Pharmaceutical company Glenmark Pharmaceuticals announced on Thursday that it has received approval from the U.S. Food and Drug Administration (FDA) for its product Fluticasone Propionate Nasal Spray.
The company stated in documentation filed with exchange registries that the Glenmark spray is bioequivalent and therapeutically equivalent to the reference drug Flonase Nasal Spray manufactured by Haleon US Holdings LLC, and will be distributed in the U.S. through Glenmark Pharmaceuticals Inc, USA.
According to sales data from IQVIA for the 12 months ending June 2026, the Flonase Nasal Spray market, including the brand itself and all available therapeutic equivalents, showed an annual sales volume of approximately $295.2 million.
Mark Kikuchi, President and Head of Business for Glenmark in North America, stated: 'The approval of Fluticasone Propionate Nasal Spray marks another step in expanding our respiratory portfolio in the U.S. and builds upon the strong foundation we have laid in this therapeutic area. We continue to strive to expand access to high-quality and affordable treatment options that meet the changing needs of patients and healthcare professionals.'
Glenmark Pharmaceuticals' Financial Results for the First Quarter
At the end of last month, Glenmark reported a multiple increase in consolidated profit after tax to 482.83 crore rupees in the first quarter of fiscal year 27, driven by strong revenue growth and a low base effect. In the corresponding quarter of the previous fiscal year, consolidated profit after tax was 46.97 crore rupees.
Furthermore, the company reported in the exchange registry that total consolidated operating income in the first quarter of the current fiscal year reached 4,018.48 crore rupees compared to 3,264.44 crore rupees for the same period a year earlier.